APO Research
Talk to an analyst

APO RESEARCH · REPORT

Klebsiella Pneumoniae Infection Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032

22 December 2025114 pages

Choose your research edition.

Industry ResearchKlebsiella Pneumoniae Infection Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Klebsiella Pneumoniae Infection Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Klebsiella Pneumoniae Infection Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Klebsiella Pneumoniae Infection Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Klebsiella Pneumoniae Infection Drug Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Klebsiella Pneumoniae Infection Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Klebsiella Pneumoniae Infection Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Klebsiella Pneumoniae Infection Drug include Acies Bio doo, Appili Therapeutics, Debiopharm International SA, Evaxion Biotech ApS, FOB Synthesis Inc, ImmunoClin Corp, Innovation Pharmaceuticals Inc, Kyorin Pharmaceutical Co Ltd and Melinta Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Klebsiella Pneumoniae Infection Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Klebsiella Pneumoniae Infection Drug market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Klebsiella Pneumoniae Infection Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Klebsiella Pneumoniae Infection Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Klebsiella Pneumoniae Infection Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Klebsiella Pneumoniae Infection Drug Market by Company

Acies Bio doo

Appili Therapeutics

Debiopharm International SA

Evaxion Biotech ApS

FOB Synthesis Inc

ImmunoClin Corp

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Pfizer Inc

F. Hoffmann-La Roche Ltd

Klebsiella Pneumoniae Infection Drug Segment by Type

ATI-1503

CA-824

CC-1807

Cefiderocol

Debio-1454

EBX-004

Others

Klebsiella Pneumoniae Infection Drug Segment by Application

Hospital

Clinic

Others

Klebsiella Pneumoniae Infection Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Klebsiella Pneumoniae Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Klebsiella Pneumoniae Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Klebsiella Pneumoniae Infection Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Klebsiella Pneumoniae Infection Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Klebsiella Pneumoniae Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of ATI-1503 Table 2. Major Company of CA-824 Table 3. Major Company of CC-1807 Table 4. Major Company of Cefiderocol Table 5. Major Company of Debio-1454 Table 6. Major Company of EBX-004 Table 7. Major Company of Others Table 8. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 10. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type (2021-2026) Table 11. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 12. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type (2021-2026) Table 13. Global Klebsiella Pneumoniae Infection Drug Price by Type (2021-2026) & (US$/unit) Table 14. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (k units) Table 15. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type (2027-2032) Table 16. Global Klebsiella Pneumoniae Infection Drug Sales by Type (2027-2032) & (US$ Million) Table 17. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type (2027-2032) Table 18. Global Klebsiella Pneumoniae Infection Drug Price by Type (2027-2032) & (US$/unit) Table 19. North America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 20. North America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Europe Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 22. Europe Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 24. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 26. Latin America Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (k units) Table 28. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Type (2021-2026) & (US$ Million) Table 29. Klebsiella Pneumoniae Infection Drug Industry Trends Table 30. Klebsiella Pneumoniae Infection Drug Industry Drivers Table 31. Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges Table 32. Klebsiella Pneumoniae Infection Drug Industry Restraints Table 33. Global Klebsiella Pneumoniae Infection Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Company (2021-2026) Table 35. Global Klebsiella Pneumoniae Infection Drug Sales by Company (2021-2026) & (k units) Table 36. Global Klebsiella Pneumoniae Infection Drug Sales Share by Company (2021-2026) Table 37. Global Klebsiella Pneumoniae Infection Drug Market Price by Company (2021-2026) & (US$/unit) Table 38. Global Klebsiella Pneumoniae Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global Klebsiella Pneumoniae Infection Drug Major Company Production Sites and Headquarters Table 40. Global Klebsiella Pneumoniae Infection Drug Company, Product Type & Application Table 41. Global Klebsiella Pneumoniae Infection Drug Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global Klebsiella Pneumoniae Infection Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global Klebsiella Pneumoniae Infection Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (k units) Table 46. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Region (2021-2026) Table 47. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2021-2026) & (US$ Million) Table 48. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Region (2021-2026) Table 49. Global Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 50. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032) & (k units) Table 51. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Region (2027-2032) Table 52. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2027-2032) & (US$ Million) Table 53. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Region (2027-2032) Table 54. Global Klebsiella Pneumoniae Infection Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 55. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 57. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application (2021-2026) Table 58. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 59. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application (2021-2026) Table 60. Global Klebsiella Pneumoniae Infection Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (k units) Table 62. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application (2027-2032) Table 63. Global Klebsiella Pneumoniae Infection Drug Sales by Application (2027-2032) & (US$ Million) Table 64. Global Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application (2027-2032) Table 65. Global Klebsiella Pneumoniae Infection Drug Price by Application (2027-2032) & (US$/unit) Table 66. North America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 67. North America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Europe Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 69. Europe Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 71. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 73. Latin America Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (k units) Table 75. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Application (2021-2026) & (US$ Million) Table 76. Acies Bio doo Company Information Table 77. Acies Bio doo Business Overview Table 78. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio Table 80. Acies Bio doo Recent Development Table 81. Appili Therapeutics Company Information Table 82. Appili Therapeutics Business Overview Table 83. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio Table 85. Appili Therapeutics Recent Development Table 86. Debiopharm International SA Company Information Table 87. Debiopharm International SA Business Overview Table 88. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio Table 90. Debiopharm International SA Recent Development Table 91. Evaxion Biotech ApS Company Information Table 92. Evaxion Biotech ApS Business Overview Table 93. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 95. Evaxion Biotech ApS Recent Development Table 96. FOB Synthesis Inc Company Information Table 97. FOB Synthesis Inc Business Overview Table 98. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 100. FOB Synthesis Inc Recent Development Table 101. ImmunoClin Corp Company Information Table 102. ImmunoClin Corp Business Overview Table 103. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio Table 105. ImmunoClin Corp Recent Development Table 106. Innovation Pharmaceuticals Inc Company Information Table 107. Innovation Pharmaceuticals Inc Business Overview Table 108. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 110. Innovation Pharmaceuticals Inc Recent Development Table 111. Kyorin Pharmaceutical Co Ltd Company Information Table 112. Kyorin Pharmaceutical Co Ltd Business Overview Table 113. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 115. Kyorin Pharmaceutical Co Ltd Recent Development Table 116. Melinta Therapeutics Inc Company Information Table 117. Melinta Therapeutics Inc Business Overview Table 118. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 120. Melinta Therapeutics Inc Recent Development Table 121. Nosopharm SAS Company Information Table 122. Nosopharm SAS Business Overview Table 123. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 124. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio Table 125. Nosopharm SAS Recent Development Table 126. Peptilogics Inc Company Information Table 127. Peptilogics Inc Business Overview Table 128. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 129. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 130. Peptilogics Inc Recent Development Table 131. Phico Therapeutics Ltd Company Information Table 132. Phico Therapeutics Ltd Business Overview Table 133. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 134. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 135. Phico Therapeutics Ltd Recent Development Table 136. Sarepta Therapeutics Inc Company Information Table 137. Sarepta Therapeutics Inc Business Overview Table 138. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 139. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 140. Sarepta Therapeutics Inc Recent Development Table 141. Shionogi & Co Ltd Company Information Table 142. Shionogi & Co Ltd Business Overview Table 143. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 144. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 145. Shionogi & Co Ltd Recent Development Table 146. Syntiron LLC Company Information Table 147. Syntiron LLC Business Overview Table 148. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 149. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio Table 150. Syntiron LLC Recent Development Table 151. Tetraphase Pharmaceuticals Inc Company Information Table 152. Tetraphase Pharmaceuticals Inc Business Overview Table 153. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 154. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 155. Tetraphase Pharmaceuticals Inc Recent Development Table 156. Pfizer Inc Company Information Table 157. Pfizer Inc Business Overview Table 158. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 159. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio Table 160. Pfizer Inc Recent Development Table 161. F. Hoffmann-La Roche Ltd Company Information Table 162. F. Hoffmann-La Roche Ltd Business Overview Table 163. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 164. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio Table 165. F. Hoffmann-La Roche Ltd Recent Development Table 166. North America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 167. North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 168. North America Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 169. North America Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032) & (k units) Table 170. North America Klebsiella Pneumoniae Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 171. North America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. North America Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 173. North America Klebsiella Pneumoniae Infection Drug Market Share by Country (2021-2026) Table 174. North America Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. North America Klebsiella Pneumoniae Infection Drug Market Share Forecast by Country (2027-2032) Table 176. Europe Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 177. Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 178. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 179. Europe Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032) & (k units) Table 180. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 181. Europe Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Europe Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 183. Europe Klebsiella Pneumoniae Infection Drug Market Share by Country (2021-2026) Table 184. Europe Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Europe Klebsiella Pneumoniae Infection Drug Market Share Forecast by Country (2027-2032) Table 186. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 187. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 188. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 189. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032) & (k units) Table 190. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 191. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 193. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Share by Country (2021-2026) Table 194. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Share Forecast by Country (2027-2032) Table 196. Latin America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 197. Latin America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 198. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 199. Latin America Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032) & (k units) Table 200. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 201. Latin America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 202. Latin America Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 203. Latin America Klebsiella Pneumoniae Infection Drug Market Share by Country (2021-2026) Table 204. Latin America Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 205. Latin America Klebsiella Pneumoniae Infection Drug Market Share Forecast by Country (2027-2032) Table 206. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 207. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026) & (k units) Table 208. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share by Country (2021-2026) Table 209. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032) & (k units) Table 210. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share Forecast by Country (2027-2032) Table 211. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 212. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026) & (US$ Million) Table 213. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Share by Country (2021-2026) Table 214. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 215. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Share Forecast by Country (2027-2032) Table 216. Key Raw Materials Table 217. Raw Materials Key Suppliers Table 218. Klebsiella Pneumoniae Infection Drug Distributors List Table 219. Klebsiella Pneumoniae Infection Drug Customers List Table 220. Research Programs/Design for This Report Table 221. Authors List of This Report Table 222. Secondary Sources Table 223. Primary Sources List of Figures Figure 1. Klebsiella Pneumoniae Infection Drug Image Figure 2. Global Klebsiella Pneumoniae Infection Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Klebsiella Pneumoniae Infection Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Klebsiella Pneumoniae Infection Drug Sales (2021-2032) & (k units) Figure 5. ATI-1503 Image Figure 6. Global ATI-1503 Sales YoY Growth (2021-2032) & (k units) Figure 7. CA-824 Image Figure 8. Global CA-824 Sales YoY Growth (2021-2032) & (k units) Figure 9. CC-1807 Image Figure 10. Global CC-1807 Sales YoY Growth (2021-2032) & (k units) Figure 11. Cefiderocol Image Figure 12. Global Cefiderocol Sales YoY Growth (2021-2032) & (k units) Figure 13. Debio-1454 Image Figure 14. Global Debio-1454 Sales YoY Growth (2021-2032) & (k units) Figure 15. EBX-004 Image Figure 16. Global EBX-004 Sales YoY Growth (2021-2032) & (k units) Figure 17. Others Image Figure 18. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 19. Global Klebsiella Pneumoniae Infection Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global Klebsiella Pneumoniae Infection Drug Market Share by Type 2025 VS 2032 Figure 21. North America Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type in 2025 Figure 22. North America Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type in 2025 Figure 23. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type in 2025 Figure 24. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type in 2025 Figure 27. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type in 2025 Figure 28. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 Klebsiella Pneumoniae Infection Drug Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 35. Clinic Image Figure 36. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 39. Global Klebsiella Pneumoniae Infection Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Klebsiella Pneumoniae Infection Drug Market Share by Application 2025 VS 2032 Figure 41. North America Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application in 2025 Figure 42. North America Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application in 2025 Figure 43. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application in 2025 Figure 44. Europe Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application in 2025 Figure 47. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Market Share in Value by Application in 2025 Figure 51. North America Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. North America Klebsiella Pneumoniae Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Klebsiella Pneumoniae Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Europe Klebsiella Pneumoniae Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Klebsiella Pneumoniae Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Latin America Klebsiella Pneumoniae Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Klebsiella Pneumoniae Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 68. Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Klebsiella Pneumoniae Infection Drug Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Klebsiella Pneumoniae Infection Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • ATI-1503
  • CA-824
  • CC-1807
  • Cefiderocol
  • Debio-1454
  • EBX-004
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Acies Bio doo
  • Appili Therapeutics
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Innovation Pharmaceuticals Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co Ltd
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Klebsiella Pneumoniae Infection Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Klebsiella Pneumoniae Infection Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Klebsiella Pneumoniae Infection Drug Market by Type
  6. 1.3.1 ATI-1503
  7. 1.3.2 CA-824
  8. 1.3.3 CC-1807
  9. 1.3.4 Cefiderocol
  10. 1.3.5 Debio-1454
  11. 1.3.6 EBX-004
  12. 1.3.7 Others
  13. 1.4 Global Klebsiella Pneumoniae Infection Drug Market Size by Type
  14. 1.4.1 Global Klebsiella Pneumoniae Infection Drug Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global Klebsiella Pneumoniae Infection Drug Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global Klebsiella Pneumoniae Infection Drug Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America Klebsiella Pneumoniae Infection Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe Klebsiella Pneumoniae Infection Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America Klebsiella Pneumoniae Infection Drug Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Klebsiella Pneumoniae Infection Drug Industry Trends
  2. 2.2 Klebsiella Pneumoniae Infection Drug Industry Drivers
  3. 2.3 Klebsiella Pneumoniae Infection Drug Industry Opportunities and Challenges
  4. 2.4 Klebsiella Pneumoniae Infection Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Klebsiella Pneumoniae Infection Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Klebsiella Pneumoniae Infection Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Klebsiella Pneumoniae Infection Drug Price (2021-2026)
  4. 3.4 Global Klebsiella Pneumoniae Infection Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Klebsiella Pneumoniae Infection Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Klebsiella Pneumoniae Infection Drug Company, Product Type & Application
  7. 3.7 Global Klebsiella Pneumoniae Infection Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Klebsiella Pneumoniae Infection Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Klebsiella Pneumoniae Infection Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Klebsiella Pneumoniae Infection Drug Tier 1, Tier 2, and Tier 3
4 Klebsiella Pneumoniae Infection Drug Regional Status and Outlook
  1. 4.1 Global Klebsiella Pneumoniae Infection Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Klebsiella Pneumoniae Infection Drug Historic Market Size by Region
  3. 4.2.1 Global Klebsiella Pneumoniae Infection Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Klebsiella Pneumoniae Infection Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Klebsiella Pneumoniae Infection Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Klebsiella Pneumoniae Infection Drug Forecasted Market Size by Region
  7. 4.3.1 Global Klebsiella Pneumoniae Infection Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Klebsiella Pneumoniae Infection Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Klebsiella Pneumoniae Infection Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Klebsiella Pneumoniae Infection Drug by Application
  1. 5.1 Klebsiella Pneumoniae Infection Drug Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Klebsiella Pneumoniae Infection Drug Market Size by Application
  6. 5.2.1 Global Klebsiella Pneumoniae Infection Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Klebsiella Pneumoniae Infection Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Klebsiella Pneumoniae Infection Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Klebsiella Pneumoniae Infection Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Klebsiella Pneumoniae Infection Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Klebsiella Pneumoniae Infection Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Acies Bio doo
  2. 6.1.1 Acies Bio doo Company Information
  3. 6.1.2 Acies Bio doo Business Overview
  4. 6.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Product Portfolio
  6. 6.1.5 Acies Bio doo Recent Developments
  7. 6.2 Appili Therapeutics
  8. 6.2.1 Appili Therapeutics Company Information
  9. 6.2.2 Appili Therapeutics Business Overview
  10. 6.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product Portfolio
  12. 6.2.5 Appili Therapeutics Recent Developments
  13. 6.3 Debiopharm International SA
  14. 6.3.1 Debiopharm International SA Company Information
  15. 6.3.2 Debiopharm International SA Business Overview
  16. 6.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product Portfolio
  18. 6.3.5 Debiopharm International SA Recent Developments
  19. 6.4 Evaxion Biotech ApS
  20. 6.4.1 Evaxion Biotech ApS Company Information
  21. 6.4.2 Evaxion Biotech ApS Business Overview
  22. 6.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product Portfolio
  24. 6.4.5 Evaxion Biotech ApS Recent Developments
  25. 6.5 FOB Synthesis Inc
  26. 6.5.1 FOB Synthesis Inc Company Information
  27. 6.5.2 FOB Synthesis Inc Business Overview
  28. 6.5.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  30. 6.5.5 FOB Synthesis Inc Recent Developments
  31. 6.6 ImmunoClin Corp
  32. 6.6.1 ImmunoClin Corp Company Information
  33. 6.6.2 ImmunoClin Corp Business Overview
  34. 6.6.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product Portfolio
  36. 6.6.5 ImmunoClin Corp Recent Developments
  37. 6.7 Innovation Pharmaceuticals Inc
  38. 6.7.1 Innovation Pharmaceuticals Inc Company Information
  39. 6.7.2 Innovation Pharmaceuticals Inc Business Overview
  40. 6.7.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  42. 6.7.5 Innovation Pharmaceuticals Inc Recent Developments
  43. 6.8 Kyorin Pharmaceutical Co Ltd
  44. 6.8.1 Kyorin Pharmaceutical Co Ltd Company Information
  45. 6.8.2 Kyorin Pharmaceutical Co Ltd Business Overview
  46. 6.8.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  48. 6.8.5 Kyorin Pharmaceutical Co Ltd Recent Developments
  49. 6.9 Melinta Therapeutics Inc
  50. 6.9.1 Melinta Therapeutics Inc Company Information
  51. 6.9.2 Melinta Therapeutics Inc Business Overview
  52. 6.9.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  54. 6.9.5 Melinta Therapeutics Inc Recent Developments
  55. 6.10 Nosopharm SAS
  56. 6.10.1 Nosopharm SAS Company Information
  57. 6.10.2 Nosopharm SAS Business Overview
  58. 6.10.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product Portfolio
  60. 6.10.5 Nosopharm SAS Recent Developments
  61. 6.11 Peptilogics Inc
  62. 6.11.1 Peptilogics Inc Company Information
  63. 6.11.2 Peptilogics Inc Business Overview
  64. 6.11.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  66. 6.11.5 Peptilogics Inc Recent Developments
  67. 6.12 Phico Therapeutics Ltd
  68. 6.12.1 Phico Therapeutics Ltd Company Information
  69. 6.12.2 Phico Therapeutics Ltd Business Overview
  70. 6.12.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  72. 6.12.5 Phico Therapeutics Ltd Recent Developments
  73. 6.13 Sarepta Therapeutics Inc
  74. 6.13.1 Sarepta Therapeutics Inc Company Information
  75. 6.13.2 Sarepta Therapeutics Inc Business Overview
  76. 6.13.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  78. 6.13.5 Sarepta Therapeutics Inc Recent Developments
  79. 6.14 Shionogi & Co Ltd
  80. 6.14.1 Shionogi & Co Ltd Company Information
  81. 6.14.2 Shionogi & Co Ltd Business Overview
  82. 6.14.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  84. 6.14.5 Shionogi & Co Ltd Recent Developments
  85. 6.15 Syntiron LLC
  86. 6.15.1 Syntiron LLC Company Information
  87. 6.15.2 Syntiron LLC Business Overview
  88. 6.15.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Product Portfolio
  90. 6.15.5 Syntiron LLC Recent Developments
  91. 6.16 Tetraphase Pharmaceuticals Inc
  92. 6.16.1 Tetraphase Pharmaceuticals Inc Company Information
  93. 6.16.2 Tetraphase Pharmaceuticals Inc Business Overview
  94. 6.16.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  96. 6.16.5 Tetraphase Pharmaceuticals Inc Recent Developments
  97. 6.17 Pfizer Inc
  98. 6.17.1 Pfizer Inc Company Information
  99. 6.17.2 Pfizer Inc Business Overview
  100. 6.17.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Product Portfolio
  102. 6.17.5 Pfizer Inc Recent Developments
  103. 6.18 F. Hoffmann-La Roche Ltd
  104. 6.18.1 F. Hoffmann-La Roche Ltd Company Information
  105. 6.18.2 F. Hoffmann-La Roche Ltd Business Overview
  106. 6.18.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product Portfolio
  108. 6.18.5 F. Hoffmann-La Roche Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Klebsiella Pneumoniae Infection Drug Sales by Country
  2. 7.1.1 North America Klebsiella Pneumoniae Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Klebsiella Pneumoniae Infection Drug Market Size by Country
  6. 7.2.1 North America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Klebsiella Pneumoniae Infection Drug Sales by Country
  2. 8.1.1 Europe Klebsiella Pneumoniae Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Klebsiella Pneumoniae Infection Drug Market Size by Country
  6. 8.2.1 Europe Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Country
  2. 9.1.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Klebsiella Pneumoniae Infection Drug Sales by Country
  2. 10.1.1 South America Klebsiella Pneumoniae Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Klebsiella Pneumoniae Infection Drug Market Size by Country
  6. 10.2.1 South America Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country
  2. 11.1.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Klebsiella Pneumoniae Infection Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Klebsiella Pneumoniae Infection Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
  2. 12.1.1 Klebsiella Pneumoniae Infection Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Klebsiella Pneumoniae Infection Drug Production Mode & Process
  7. 12.2 Klebsiella Pneumoniae Infection Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Klebsiella Pneumoniae Infection Drug Distributors
  10. 12.2.3 Klebsiella Pneumoniae Infection Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst